Psoriatic Disease News

Boehringer Ingelheim has partnered with Quallent Pharmaceuticals to expand access to its Humira biosimilar citrate-free adalimumab-adbm in the United States, according to a company press release.

DESTIN, Fla. — The course of difficult-to-treat psoriatic arthritis can be significantly impacted by a host of factors beyond choice of therapy, according to data presented at the Congress of Clinical Rheumatology East annual meeting.

Patients with psoriatic arthritis demonstrated similar disease activity outcomes and drug persistence after long-term treatment with either etanercept or its biosimilar SB4, according to data published in Arthritis Care & Research.

The FDA has approved a citrate-free, high-concentration formulation of the interchangeable adalimumab biosimilar Cyltezo to treat multiple chronic inflammatory diseases, according to the manufacturer.

Healio has compiled April’s most-read news in dermatology.

Healio spoke with Matthew Lewis, MD, about the risk for psoriatic arthritis in patients with psoriasis.

The FDA has approved Selarsdi as a biosimilar to Stelara for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis, Teva Pharmaceuticals and Alvotech announced in a press release.

Patients with psoriatic arthritis who receive deucravacitinib report significant improvements in mental health, pain, fatigue and other outcomes vs. placebo, according to data published in Arthritis Care & Research.

Tildrakizumab was efficacious in the treatment of patients with moderate to severe plaque psoriasis affecting the scalp and presented no new safety signals, according to a study.

Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just 16% can say the same for all other adalimumab biosimilars combined, according to a market analysis from Spherix Global Insights.